OVERVIEW

Clinical Briefings™: Diagnosing and Treating Mucopolysaccharidosis type I (MPS I): Opportunities to Improve Prognosis is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Activity Overview:
This CME online activity, Clinical Briefings™: Diagnosing and Treating MPS I: Opportunities to Improve Prognosis, features written content complimented by audio commentary from Paul Orchard, MD, a pediatrician and expert in the field of cell therapies for inherited metabolic diseases. This activity provides an overview of lysosomal storage disorders with a focus on mucopolysaccharidosis type I (MPS I), characteristic features and diagnostic assessment in this setting, and current and novel treatments for individuals who have received a diagnosis of this disease.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Review the pathophysiology of MPS I
• Recognize the clinical presentation and diagnostic evaluation of MPS I
• Evaluate the limitations in the historical standard of care
• Discuss the efficacy and safety of enzyme replacement therapy and emerging therapies for patients with MPS I

Benefits of Participating:
• Recognize characteristic features of MPS I for early diagnosis
• Determine newborn screening recommendations in the state where you practice
• Explain care decisions to patients and caregivers
• Discuss clinical data of new therapies for MPS I with your colleagues
• Learn something new about lysosomal storage disorders and earn continuing medical education (CME) credit.